Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glycogen Response to Enzyme Replacement Therapy in Pompe Disease
2023-508000-37-01Phase 4Authorised
- Sponsor
- Rigshospitalet
- Start
- Jan 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of avalglucosidase alfa in Pompe disease, sponsored by Rigshospitalet. Planned start Jan 2024; status: authorised.
02
Drugs
avalglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on 2023-508000-37-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508000-37-01.